Drug Type Small molecule drug |
Synonyms EC359 |
Target |
Action inhibitors |
Mechanism LIFR inhibitors(LIF receptor subunit alpha inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Inflammatory Breast Neoplasms | Preclinical | United States | 28 Apr 2025 | |
Inflammatory Breast Neoplasms | Preclinical | United States | 28 Apr 2025 | |
Ovarian Cancer | Preclinical | United States | 22 Mar 2024 | |
Ovarian Cancer | Preclinical | United States | 22 Mar 2024 | |
Endometrial Carcinoma | Preclinical | United States | 13 Dec 2023 | |
Endometrial Carcinoma | Preclinical | United States | 13 Dec 2023 | |
Pancreatic Cancer | Preclinical | United States | 19 Apr 2018 | |
Non-Small Cell Lung Cancer | Preclinical | United States | 17 Apr 2018 | |
Colorectal Cancer | Preclinical | United States | 16 Apr 2018 | |
Breast Cancer | Preclinical | United States | 28 Mar 2018 |